Shares in Stratagene rose 28.8 percent for the four-day trading week ended Tuesday after Agilent signed a deal to buy the firm for $10.94 a share (see related article this issue). The acquisition price represents a 28 percent premium over Stratagene’s closing price the day before the deal was announced.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.